Jubilant Pharmova cash flow

Latest FY26

Cash from operations: ₹1,227cr+14.4% on FY25
Capital spending: ₹1,449cr+29.9% on FY25
Free cash flow: −₹222cr−₹43.5 cr in FY25
Cash from financing: ₹94.9cr−₹1,453 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	440	369	382	554
	—	212	240	272	188
	—	−25.2	−36.6	−26.1	−9.8
	—	−3.1	1.7	−0.2	5.0
	—	11.8	4.3	8.5	3.7
	—	−6.4	0.1	1.4	−5.4
	—	47.6	−361	142	59.5
	—	5.5	0.0	0.0	0.0
	—	−44.9	78.5	90.8	−64.7
	—	−99.5	24.2	49.4	38.6
	—	−5.2	−29.2	56.8	144
	—	110	55.3	23.2	211
	—	179	−17.0	32.9	−274
Cash from operating activities
	546	614	981	146	15.5
	—	822	329	1,033	849
	—	1,436	1,311	1,179	865
	—	209	238	208	204
	—	1,227	1,072	971	661
Cash from investing activities
	—	1,449	1,116	898	814
	—	102	5.0	9.7	18.6
	—	0.0	1.4	7.8	12.7
	—	0.0	952	5.7	0.9
	—	0.0	0.0	0.0	8.8
	—	79.3	610	230	245
	—	24.4	38.4	25.7	10.0
	—	−16.7	−0.3	26.6	−0.1
	—	−1,260	488	−608	−544
Cash from financing activities
	—	0.0	0.9	0.0	0.0
	—	0.0	5.6	0.0	0.0
	—	2,571	27.4	117	3,005
	—	2,070	1,100	138	2,773
	—	70.9	59.8	61.2	70.1
	—	238	236	244	234
	—	79.5	79.6	79.8	80.1
	—	−18.0	0.0	−27.4	−4.0
	—	94.9	−1,453	−433	−157
	—	61.7	107	−69.1	−40.4
	—	117	24.8	11.6	70.5
	—	179	132	−57.5	30.1
	—	1,267	1,088	956	1,014
Reference items
	1,218	1,260	1,174	901	776
	14.2%	15.2%	16.2%	13.4%	12.4%
	−222	−222	−43.5	73.6	−154
	—	322	−1,256	−166	—
	−₹14.07	−₹14.07	−₹2.75	₹4.66	−₹9.73
	—	3.09×	1.28×	13.36×	−10.18×
	—	209	238	208	204
	—	238	236	244	234

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JUBLPHARMA₹946.00

Jubilant Pharmova Ltd.

· Pharma & Health

₹ CrorePeersGLAND PPLPHARMA KIMS INDGN ONESOURCE GRANULES PFIZER POLYMEDMcap ₹14,947 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	554.0	381.9	368.6	440.4	—
+ Finance Costs	188.2	272.3	240.3	211.8	—
+ Interest Income	-9.8	-26.1	-36.6	-25.2	—
+ Fair Value (Gains) / Losses	5.0	-0.2	1.7	-3.1	—
+ Share-based Payments	3.7	8.5	4.3	11.8	—
+ Unrealised FX (Gain) / Loss	-5.4	1.4	0.1	-6.4	—
+ Other Non-cash Items	59.5	141.7	-360.8	47.6	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	0.0	5.5	—
Changes in Working Capital
+ Inventories	-64.7	90.8	78.5	-44.9	—
+ Trade Receivables — Current	38.6	49.4	24.2	-99.5	—
+ Other Current Assets	144.1	56.8	-29.2	-5.2	—
+ Trade Payables — Current	210.5	23.2	55.3	109.9	—
+ Other Current Liabilities	-274.2	32.9	-17.0	179.1	—
Cash from Operating Activities
Profit Before Tax (per I/S)	15.5	146.4	981.1	614.4	546.3
+ Total Adjustments (incl. Working Capital)	849.4	1,032.6	329.4	821.8	—
Cash from Operations (pre-tax)	865.0	1,179.0	1,310.5	1,436.2	—
+ Income Taxes Paid	204.3	207.7	238.4	209.4	—
Cash from Operating Activities	660.7	971.3	1,072.1	1,226.8	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	814.5	897.7	1,115.6	1,449.1	—
+ Disp of Fixed Assets	18.6	9.7	5.0	102.1	—
+ Purchase of Investments (Equity / Debt)	12.7	7.8	1.4	0.0	—
+ Sale of Investments (Equity / Debt)	0.9	5.7	952.1	0.0	—
+ Share of Profits — Partnership Firms / LLPs	8.8	0.0	0.0	0.0	—
+ Government Grants Received	244.5	229.9	609.5	79.3	—
+ Interest Received — Investing	10.0	25.7	38.4	24.4	—
+ Other Inflows / (Outflows) — Investing	-0.1	26.6	-0.3	-16.7	—
Cash from Investing Activities	-544.4	-607.9	487.7	-1,260.0	—
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options	0.0	0.0	0.9	0.0	—
+ Buyback / Redemption of Own Shares	0.0	0.0	5.6	0.0	—
+ Proceeds from Borrowings	3,004.7	117.2	27.4	2,571.3	—
+ Repayment of Borrowings	2,773.0	137.6	1,100.4	2,069.7	—
+ Payment of Lease Liabilities	70.1	61.2	59.8	70.9	—
+ Interest Paid	234.2	243.7	235.6	238.3	—
+ Dividends Paid	80.1	79.8	79.6	79.5	—
+ Other Inflows / (Outflows) — Financing	-4.0	-27.4	0.0	-18.0	—
Cash from Financing Activities	-156.7	-432.5	-1,452.7	94.9	—
Net Changes in Cash (pre-FX)	-40.4	-69.1	107.1	61.7	—
+ Effect of FX Rate Changes on Cash	70.5	11.6	24.8	117.1	—
Net Changes in Cash	30.1	-57.5	131.9	178.8	—
Closing Cash	1,013.9	956.4	1,088.3	1,267.1	—
Reference Items
EBITDA	776.3	900.8	1,173.7	1,259.8	1,218.2
EBITDA Margin %	12.36	13.44	16.22	15.22	14.15
Free Cash Flow (CFO − Capex)	-153.8	73.6	-43.5	-222.3	-222.3
Free Cash Flow to Equity	—	-166.1	-1,256.3	322.0	—
Free Cash Flow per Basic Share	-9.73	4.66	-2.75	-14.07	-14.07
Cash Flow to Net Income	-10.18	13.36	1.28	3.09	—
Cash Paid for Taxes	204.3	207.7	238.4	209.4	—
Cash Paid for Interest	234.2	243.7	235.6	238.3	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.